The invention refers to the form of oral solid-state drug management, including 5-chloro-n - (- (5S) - 2-oxo-3 - [4 - (3-oxo-4-morfolini) phenyl] - 1, 3-oxazolidin-5-il -, methyl) - 2-endosulfan (rivaroxab, active compound (I)),It is characterized by rapid release of some active compounds (I) and partial controlled release (correction, delay, delay),Procedures for preparation, use as drugs and for prevention, secondary prevention or treatment of disordersVer anexos